The global pharmaceutical lipid-based excipients market size was estimated at USD 1,825.0 million in 2024 and is projected to reach USD 2,420.9 million by 2030, growing at a CAGR of 4.8% from 2025 to 2030. This growth is largely attributed to the increasing prevalence of poorly soluble drug candidates, which represent nearly 39% of marketed drugs and approximately 87% of pipeline candidates. Poor aqueous solubility remains one of the most critical challenges in drug development, often leading to reduced bioavailability and inconsistent therapeutic outcomes. As a result, pharmaceutical manufacturers are increasingly adopting advanced excipient solutions, particularly lipid-based excipients, to enhance solubility and absorption. Supporting this trend, a 2023 study published in the European Journal of Pharmaceutical Sciences demonstrated that supersaturated lipid-based formulations significantly improve drug absorption for compounds with poor biopharmaceutical properties, reinforcing their growing importance in modern drug formulation.

The integration of lipid-based excipients in mRNA vaccines and gene therapies has emerged as a major growth catalyst for the market, especially highlighted during the development and large-scale deployment of mRNA vaccines throughout the COVID-19 pandemic. Lipid excipients play a critical role in stabilizing and delivering nucleic acid-based drugs by protecting them from degradation and facilitating cellular uptake. A formulation scientist specializing in nucleic acid-based drugs emphasized that the adoption of lipid excipients in RNA-based therapies represents a transformative phase in pharmaceutical development, enabling entirely new therapeutic modalities. Additionally, increasing demand for lipid excipients has been influenced by patent expirations of major pharmaceutical drugs, which have intensified market competition and reduced drug prices. This environment has further increased the need for cost-effective, high-performance excipients that can improve formulation efficiency without significantly raising development costs.

Technological advancements, particularly in artificial intelligence (AI) and formulation sciences, have further accelerated the growth of the lipid-based excipients market. AI-driven modeling tools are increasingly being used to predict excipient–drug interactions, optimize lipid composition, and accelerate formulation development, thereby reducing both development timelines and failure rates. Alongside AI, continuous innovations in excipient chemistry and formulation technologies have expanded the applicability of lipid-based systems across a wide range of drug classes. According to a 2023 study published in the Saudi Pharmaceutical Journal, lipid excipients can significantly enhance the bioavailability of lipophilic drugs by improving solubility, permeability, and distribution, while also helping to reduce potential toxicity. These advancements continue to strengthen the role of lipid excipients as enabling components in complex pharmaceutical formulations.

Key Market Trends & Insights:

• Europe dominated the pharmaceutical lipid-based excipients market with a revenue share of 33.6% in 2024, supported by strong adoption of advanced drug delivery systems and a rising burden of chronic diseases. Countries such as Germany, France, and the UK are major contributors to regional growth, driven by sustained pharmaceutical innovation, robust research infrastructure, and regulatory alignment that supports excipient standardization and quality.
• Meanwhile, the Asia Pacific pharmaceutical lipid-based excipients market is expected to register the fastest CAGR of 5.6% during the forecast period. This growth is driven by increasing demand for lipid excipients in advanced drug delivery systems, with countries including China, India, Japan, and South Korea playing pivotal roles in formulation development, manufacturing scale-up, and global pharmaceutical supply chains.
• Based on excipient type, the oils segment dominated the market with a share of 40.5% in 2024, supported by strong demand across pharmaceutical, personal care, and industrial applications due to their versatility and compatibility with a wide range of active ingredients. In contrast, the lecithin and phospholipids segment is projected to grow at a robust CAGR of 5.5% over the forecast period. This growth is driven by ongoing research efforts aimed at overcoming formulation challenges associated with high molecular weight proteins and peptides, particularly in advanced biologic and injectable therapies.
• Based on product applications, the topical formulations segment led the market with a share of 51.4% in 2024, reflecting the widespread use of lipid excipients in enhancing formulation stability, texture, and patient compliance. These excipients improve skin penetration and product aesthetics, making them highly suitable for dermatological applications. Ophthalmic applications are expected to witness the fastest CAGR of 6.7% during the forecast period, driven by the rising incidence of dry eye disease and the growing demand for advanced ocular drug delivery systems that improve residence time and therapeutic efficacy.
• Based on disease application, the oncology segment accounted for the largest market share of 42.3% in 2024. This dominance is supported by the expanding pipeline of anti-cancer drugs, including targeted therapies and immunotherapies, which often require advanced delivery systems to achieve optimal efficacy. Cardiovascular diseases are also expected to grow significantly over the forecast period, driven by the high global prevalence of CVDs and the need for improved oral and injectable drug formulations.
• Based on industry application, the pharmaceutical (OTC & Rx) segment dominated the market with a share of 61.0% in 2024, reflecting the widespread adoption of lipid excipients in both prescription and over-the-counter drug formulations. The nutraceutical segment, encompassing dietary supplements and related products, is expected to register the fastest CAGR of 5.1% during the forecast period. This expansion is largely driven by strategic collaborations between lipid excipient manufacturers and companies specializing in nutritional supplements, aiming to improve bioavailability and consumer appeal.
• Based on age group, adult products targeting individuals aged 19–64 years dominated the market with a share of 59.6% in 2024, driven by high consumption of pharmaceuticals for chronic and lifestyle-related conditions. The geriatric products segment is projected to witness the fastest CAGR of 5.2% over the forecast period, supported by the growing elderly population and increasing demand for age-specific formulations with improved absorption and tolerability.
• Based on end use, pharmaceutical manufacturers held the largest market share of 64.9% in 2024, reflecting their central role in drug formulation and commercialization. However, Contract Development and Manufacturing Organizations (CDMOs) are expected to witness the fastest CAGR of 5.2% during the forecast period, driven by increased outsourcing of formulation development and manufacturing activities.

Order a free sample PDF of the Pharmaceutical Lipid-Based Excipients Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 1,825.0 Million
• 2030 Projected Market Size: USD 2,420.9 Million
• CAGR (2025-2030): 4.8%
• Europe: Largest market in 2024
• Asia Pacific: Fastest Growing Market

Key Companies & Market Share Insights:

The market features a mix of large multinational corporations and specialized excipient manufacturers, including ABITEC Corporation, BASF, Gattefossé, CordenPharma, Lipoid, and IOI Oleo GmbH, among others. Rising demand for lipid-based drug delivery systems, particularly in mRNA vaccines and gene therapies, has intensified competition and driven strategic partnerships, capacity expansions, and continuous innovation.

• Gattefossé is recognized for its expertise in lipid-based excipients that enhance the oral bioavailability of poorly water-soluble drugs, with its solutions increasingly adopted across development stages by 2025 to reduce development timelines and improve solubility and stability.
• Croda International PLC offers a broad portfolio of high-purity pharmaceutical excipients, including specialized lipids and surfactants, which have played a key role in improving drug solubility, stability, and delivery across a wide range of pharmaceutical formulations.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.